Abstract: A gesture-based wake process for an AR system is described herein. The AR system places a hand-tracking input pipeline of the AR system in a suspended mode. A camera component of the hand-tracking input pipeline detects a possible visual wake command being made by a user of the AR system. On the basis of detecting the possible visual wake command, the AR system wakes the hand-tracking input pipeline and places the camera component in a fully operational mode. If the AR system, using the hand-tracking input pipeline, verifies the possible visual wake command as an actual wake command, the AR system initiates execution of an AR application.

Abstract: Provided herein is a computing system including a processor in communication with at least one memory. The processor is configured to (i) build a model using historical vehicle telematics data and historical vehicle data, the model configured to: (a) predict an operating cost of a vehicle based upon a vehicle type and user data and (b) output operational parameters for operating the vehicle, (ii) receive a vehicle acquisition request for a selected vehicle including vehicle data for the selected vehicle and selected user data for the user of the selected vehicle, (iii) input the vehicle acquisition request data into the model, and (iv) output from the model an acquisition cost and operational parameters for the selected vehicle and the selected user including a procurement cost for the selected vehicle and an operating cost for operating the selected vehicle within the operational parameters for a predetermined time period.

Abstract: Provided herein is a computing system including a processor in communication with at least one memory. The processor is configured to (i) build a model using historical vehicle telematics data and historical vehicle data, the model configured to: (a) predict an operating cost of a vehicle based upon a vehicle type and user data and (b) output operational parameters for operating the vehicle, (ii) receive a vehicle acquisition request for a selected vehicle including vehicle data for the selected vehicle and selected user data for the user of the selected vehicle, (iii) input the vehicle acquisition request data into the model, and (iv) output from the model an acquisition cost and operational parameters for the selected vehicle and the selected user including a procurement cost for the selected vehicle and an operating cost for operating the selected vehicle within the operational parameters for a predetermined time period.

Abstract: The present invention relates to methods of treating Netherton syndrome. In one embodiment, the method comprises administering to the patient (i) a serine protease inhibitor and (ii) an anti-inflammatory agent. In another embodiment, the method comprises (a) administering to the patient a serine protease inhibitor and an anti-inflammatory agent when the patient is having an outbreak of Netherton syndrome, and (b) administering a serine protease inhibitor when the patient is in remission. The present invention also relates to pharmaceutical compositions comprising (i) a serine protease inhibitor and (ii) an anti-inflammatory agent.

Abstract: The present disclosure relates generally to methods and devices for the cooling (or removal of heat from) power electronics modules in automotive vehicles, wherein the cooling is done by positioning the power electronics module in a housing, directing a fluid into the housing, and impinging the fluid onto the power electronics module and/or an electrical connection in contact with the power electronics module.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Abstract: A robotic system for a robotic limb configured to recover energy for minimizing power consumption of the robotic system, comprising a first support member, a second support member, and a quasi-passive elastic actuator rotatably coupling the first and second support members to define a joint of the robotic system rotatable about an axis of rotation defining a degree of freedom. The quasi-passive elastic actuator can comprise a first vane device and a second vane device, the first vane device and second vane device being rotatable relative to each other within the housing and defining, at least in part, a compression chamber and an expansion chamber. The system can further comprise a valve assembly, the valve assembly comprising a valve device disposed through an opening of the first vane device along the axis of rotation, and a shunt circuit facilitating fluid flow between the compression and expansion chambers through the valve assembly.

Abstract: A foot-supporting appendage of a wearable robotic exoskeleton configured to support a foot of a user wearing the robotic exoskeleton. The foot-supporting appendage can include a rearward support configured to support a hind foot portion of a foot of the user. The foot-supporting appendage can further include a frontward support configured to connect to the rearward support and configured to support a forefoot portion of the foot of the user. A size of the foot-supporting appendage is adjustable to accommodate a respective foot of a user of a plurality of users having different sizes of feet.

Abstract: Prioritizing a customer service agent's responses to customer messages. In one form, an expected response time target is determined based on a time interval between sending an agent response and receiving a customer response from a particular customer. In other forms, other objective factors, such as message intervals, customer properties, and message properties, are used to determine the expected response time target. In yet other forms, a customer conversation can be automatically closed if the customer does not respond within a predetermined maximum time interval.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Abstract: Provided herein is a computing system including a processor in communication with at least one memory. The processor is configured to (i) build a model using historical vehicle telematics data and historical vehicle data, the model configured to: (a) predict an operating cost of a vehicle based upon a vehicle type and user data and (b) output operational parameters for operating the vehicle, (ii) receive a vehicle acquisition request for a selected vehicle including vehicle data for the selected vehicle and selected user data for the user of the selected vehicle, (iii) input the vehicle acquisition request data into the model, and (iv) output from the model an acquisition cost and operational parameters for the selected vehicle and the selected user including a procurement cost for the selected vehicle and an operating cost for operating the selected vehicle within the operational parameters for a predetermined time period.

Abstract: Provided herein is a computing system including a processor in communication with at least one memory. The processor is configured to (i) build a model using historical vehicle telematics data and historical vehicle data, the model configured to: (a) predict an operating cost of a vehicle based upon a vehicle type and user data and (b) output operational parameters for operating the vehicle, (ii) receive a vehicle acquisition request for a selected vehicle including vehicle data for the selected vehicle and selected user data for the user of the selected vehicle, (iii) input the vehicle acquisition request data into the model, and (iv) output from the model an acquisition cost and operational parameters for the selected vehicle and the selected user including a procurement cost for the selected vehicle and an operating cost for operating the selected vehicle within the operational parameters for a predetermined time period.

Abstract: A pharmaceutical composition which comprises therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hour or more and the use of the composition to treat various neurological diseases.

Abstract: Described herein are examples of a system which include a boiling system and a dispensing system. The boiling system includes a primary boiler to heat hot water, a holding boiler to maintain the hot water, a brew group to receive the hot water from the holding boiler, and a heated transfer hose to receive a beverage component from the brew group and apply heat to the beverage component. The brew group includes a motor, a tamp to form a puck, a heated brew chamber to extract a beverage component, a load cell to measure a weight of the brew group, a heating element to heat the brew chamber, a spray to press the puck out, and an ejector to sweep the puck away. The dispensing system is coupled to the heated transfer hose to dispense the beverage component at a set point temperature.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Abstract: A method of facilitating switching of a quasi-passive elastic actuator of a tunable actuator joint module of a robotic system between an inelastic state and an elastic state comprising configuring a quasi-passive elastic actuator to be operable with a primary actuator of the tunable actuator joint module to selectively apply an augmented torque to assist the primary actuator in rotation of a joint of the tunable actuator joint module. The method further comprises configuring an elastic component of the quasi-passive actuator to comprise a first vane device and second vane device rotatable relative to each other within a housing, supporting a valve assembly about the axis of rotation of the joint through the first vane device, and configuring a shunt circuit to facilitate fluid flow between compression and expansion chambers through the valve assembly.

Abstract: The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof.

Abstract: There is a need to provide a collagen powder having desirable product characteristics, such as high fluid absorption capacity, while also having processing characteristics that allow commercial manufacturing and handling of the collagen powder. The present invention relates to a collagen powder, a method of manufacture thereof, and uses thereof. In particular, the present invention relates to a process for preparing a collagen powder, the process comprising the steps of providing a collagen source; adjusting the concentration of the collagen source; adjusting the pH of the collagen source; freezing the collagen source; dehydrating the frozen collagen; and degrading the dehydrated collagen to a powder.

Abstract: A pharmaceutical composition which comprises therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hour or more and the use of the composition to treat various neurological diseases.

Abstract: An apparatus for storing collectibles is disclosed. The apparatus is particularly useful for storing collectible packs of cards that are commonly sold as “booster packs” for larger decks. The apparatus has multiple rails which support the booster pack without crimping or damaging the flaps at the top and bottom of the pack. As the pack is supported by the flaps and not by friction of the body of the pack itself, the apparatus can have a larger internal space to accommodate a variety of sizes of packs having similar flaps.